Promising Results of Next-Generation Intranasal COVID-19 Booster Vaccine: Implications for Infection Prevention and Transmission
Mount Sinai Health SystemThe Icahn School of Medicine at Mount Sinai in New York, NY is pleased to announce that CastleVax, Inc. has completed enrollment and a preliminary analysis of a phase 1 trial of its licensed Newcastle disease virus (NDV)-based COVID-19 booster vaccine.